Targeted Treatment Improves Disability in Guillain-Barre Syndrome

(MedPage Today) -- SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III, placebo-controlled study...